Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.91
- Piotroski Score 3.00
- Grade Buy
- Symbol (SYRE)
- Company Spyre Therapeutics, Inc.
- Price $28.75
- Changes Percentage (-1.54%)
- Change -$0.45
- Day Low $28.41
- Day High $30.30
- Year High $47.97
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $45.00
- High Stock Price Target $71.00
- Low Stock Price Target $40.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-338,790,000
Income Statement
Quarterly
Annual
Latest News of SYRE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Selenis, Syre to open textile-to-textile recycling plant in US by 2025
A joint venture between Selenis and Syre is set to launch an advanced recycling facility in the US, producing 10,000 metric tonnes of circular polyester annually by late 2025....
By Yahoo! Finance | 2 weeks ago
